Hot melt extrusion (HME) technology is rapidly gaining popularity in the global pharmaceutical R&D field.
This technology significantly improves drug dissolution and bioavailability by mixing poorly soluble drug active ingredients with a polymer carrier in a molten state to form a solid dispersion. HME combines the advantages of solid dispersion technology and mechanical preparation, achieving dust-free, continuous operation, excellent reproducibility, and extremely high production efficiency.

In July, two Indian clients flew to Hartek specifically to inspect an HTGD-11 series pharmaceutical-grade twin-screw extruder, bringing their own pharmaceutical raw materials. This series of equipment allows for the determination of key process parameters using minimal amounts of expensive ingredients, thereby accelerating process development. The equipment reduces cleanroom space requirements and enables consistent, controllable processing.
Hartek’s pharmaceutical-grade twin-screw extruders feature a split barrel and modular screw structure, facilitating quick and easy process adjustments and cleaning. Independent zoned temperature control with an accuracy of ±1°C ensures stable processing of heat-sensitive materials.

Hartek is a national high-tech enterprise specializing in the production of polymer processing laboratory equipment, with business scope covering eight major fields: packaging, agriculture, industry, food, tobacco, medical, specialty materials, and new energy electronics. The company holds over 30 national patents and has passed ISO 9001 quality management system certification and EU CE certification. To date, it has provided equipment to more than 500 enterprises, universities, and research institutions worldwide.
The fact that the Indian customer brought their own raw materials for on-site inspection and confirmed shipment on the spot once again demonstrates Hartek’s professional strength in the field of hot melt extrusion with its pharmaceutical-grade twin-screw extruder.




